Position in BBIO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$71,140,263
+$7,949,503 QoQ
Shares Held
957,989
+16.0% QoQ
Ownership
0.489%
of shares outstanding
% of Portfolio
0.73%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 49%
Shared 0%
None 51%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026FRONTIER CAPITAL MANAGEMENT CO LLC holds $713,801,776 across 19 Biotechnology names. BBIO ranks #4 (10.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
517,284 | $97,792,540 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
1,064,483 | $89,597,534 | |
| 3 | INSM |
INSMED Inc
|
469,561 | $76,782,614 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
This page
|
957,989 | $71,140,263 | |
| 5 | KYMR |
Kymera Therapeutics, Inc.
|
759,848 | $63,287,739 | |
| 6 | PVLA |
Palvella Therapeutics, Inc.
|
374,035 | $46,623,462 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,191,182 | $45,905,262 | |
| 8 | NUVL |
Nuvalent, Inc.
|
395,546 | $40,523,687 |
All Filings in BBIO
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $71,140,263 | 957,989 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $63,190,760 | 826,131 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $34,261,338 | 659,633 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $23,134,246 | 535,763 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $26,594,735 | 769,301 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $29,521,543 | 1,075,858 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $12,810,504 | 503,162 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $3,758,161 | 148,368 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $13,899,653 | 449,536 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||